WILMINGTON, MASSACHUSETTS--(CCNMatthews - Oct. 20, 2005) - Groundbreaking Study in ARCHIVES OF DERMATOLOGY Offers Improved Treatments for Individuals Suffering From Premature Skin Damage DUSA Pharmaceuticals, Inc. (NASDAQ NMS:DUSA), today announced the final results of the first prospective, randomized, controlled, split face clinical study using Levulan® (aminolevulinic acid HCl) (“ALA”) photodynamic therapy together with intense pulsed light (IPL) for the treatment of photodamaged skin. The report was published in the October 2005 issue of the prestigious American Medical Association journal Archives of Dermatology.
